



# CTNZ Newsletter

March 2019 | Quarterly newsletter | Issue 38



CTNZ wishes to acknowledge the devastating events in Christchurch on Friday 15th March - our thoughts are with all of our friends and colleagues in Christchurch and around New Zealand affected by this tragedy

*Kia kaha*

## THE PANTOCIN STUDY IS GAINING MOMENTUM

This study has begun training sites ready to begin recruitment very soon. Patients will be invited to take part in the study from 11 sites across the country, making it CTNZ's most widespread study to date. The PantoCIN Study is a double blind placebo controlled trial with the primary aim of determining whether treatment with Pantoprazole can reduce delayed chemotherapy induced nausea and vomiting (CINV) for men and women receiving chemotherapy for breast cancer. Delayed CINV happens 24 hours or more after chemotherapy treatment. PantoCIN participants will complete questionnaires about their symptoms using an online tool (web or phone app). The study will open in the next few weeks and will recruit 160 participants in just under two years.

For further information, please contact Lou: [louise.clement@auckland.ac.nz](mailto:louise.clement@auckland.ac.nz)



# PantoCIN Study



# SAVE THE DATE

## Cancer Trials New Zealand Annual Scientific Meeting

**Thursday 24 October 2019**  
**Harbourside Function Centre, Wellington**

*CTNZ will be joining NZSO again this year with their ASM preceding the main NZSO conference (25-26 October)*



## NEWS

Last year CTNZ hosted the team from the Clinical Informatics Research Unit (University of Southampton, UK). They gave several presentations of the EDGE clinical research management system to a number of different groups within the University, UniServices, Auckland DHB and Bay of Plenty DHB.

The University and ADHB have continued to explore the values of EDGE with a view to using it from a sponsor/site management perspective. The two institutions are entering into an evaluation licence with the University of Southampton to pilot the system this year. Sarah Bengé has been invited to give a presentation at the EDGE international conference 3-4 April. She will be talking about Auckland's (and NZ's) EDGE journey so far, explaining to the wider EDGE community how clinical research is structured and takes place in NZ and how hopefully EDGE will be of benefit.

UNIVERSITY OF  
**Southampton**






# CURRENT TRIALS and STUDIES

## KISS

We are excited to have opened three additional sites for recruitment this year - North Shore Hospital, Waikato Hospital and Taranaki Hospital – and approvals are underway to open the study at Hawkes Bay in the near future. The study will now be recruiting at 9 treating hospitals around New Zealand and we're looking forward to seeing an increase in recruitment with the opening of these new sites. Twenty-three participants are currently enrolled on the study. Our recruitment target is 100 participants.



For further information about the KISS study, please contact Kate: [kate.gorton@auckland.ac.nz](mailto:kate.gorton@auckland.ac.nz)

## SOLD

Annual follow-up continues for this study. All patients will have completed their month 60 (5 years) follow-up by the end of this year. 37 patients (30% of all the SOLD Study patients) have now completed 8 years on follow-up. Well done and thank you to the patients and site staff for this amazing effort.

For further information, please contact Jade: [j.scott@auckland.ac.nz](mailto:j.scott@auckland.ac.nz)

## THYmine 2

December and January are historically quiet times for participant recruitment, although we still managed to recruit a few during that time. There are now 43 participants enrolled into the THYmine 2 Study. The fourth study site, Dunedin Hospital, opened recently and has already recruited two participants. This study aims to recruit 200 patients with gastrointestinal or metastatic breast cancer for whom the use of a schedule containing fluoropyrimidine (Capecitabine or 5-FU) is planned as a monotherapy or in combination.

Dunedin	2
Tauranga	0
Auckland	32
Canopy Care (Auckland)	9
<b>TOTAL</b>	<b>43</b>

For further information about the THYmine2 Study, please contact Rebecca: [r.hu@auckland.ac.nz](mailto:r.hu@auckland.ac.nz)

## PROSPER

This project, introducing genomics to clinic, is currently undergoing development into its next part which includes wider genomic testing for patients and providing a registry of results which links genomic data. This pioneering study continues to bring together scientists, laboratories and clinical staff to enable clinical genomic evaluation for patients. For further information, please contact either Michelle: [MiWilson@adhb.govt.nz](mailto:MiWilson@adhb.govt.nz) or Lou (CTNZ): [louise.clement@auckland.ac.nz](mailto:louise.clement@auckland.ac.nz)

## MELVAC

The study is in the final phase of data cleaning. The study team will start the final analysis soon.

For further information about MELVAC, please contact Rebecca: [r.hu@auckland.ac.nz](mailto:r.hu@auckland.ac.nz)



# CTNZ STAFF UPDATE

**Nicky Lawrence** joined us in February as our Senior Clinical Research Fellow. Nicky completed her undergraduate studies at The University of Auckland. She is a Medical Oncologist at Auckland City Hospital with an interest in genitourinary cancers and clinical trial methodology. She was awarded her Fellowship of the Royal Australasian College of Physicians in 2015. Nicky worked as a research fellow at the NHMRC Clinical Trials Centre, University of Sydney from 2015 to 2017 where she gained experience working in a co-ordinating centre for cancer clinical trials. She was awarded an NHMRC postgraduate scholarship, NZ Goldman Sachs scholarship, and Sydney Catalyst Top-Up scholarship to undertake a PhD evaluating the design of cancer clinical trials in the era of targeted and immunological therapies (2015 to 2018). She convened the inaugural NZ concept development workshop, and is a faculty member of the ACORD protocol writing workshop.



**Robert Cartwright** has been our SAS programmer for six months but from April 2019 he will take on all the Clinical Trial Data Manager tasks to work full time at CTNZ in the Data Management team with Luzi. Robert graduated from The University of Auckland in 2016 with a Bachelor of Science in Biomedical Science, and has recently completed a Master of Biomedical Science at The Liggins Institute. In his Masters, Robert investigated the influence of fetal growth restriction on the effects of repeat antenatal corticosteroid therapy for preterm birth. Robert is also an active Volunteer Ambulance Officer with St. John Ambulance.

## Enjoy the Easter break



**Contact: Sarah Benge**  
CTNZ - Discipline of Oncology  
Faculty of Medical & Health Sciences  
The University of Auckland

**Physical Address:**  
Level 1, Building 505  
85 Park Road, Grafton,  
Auckland, 1023

**Email Address:**  
[s.benge@auckland.ac.nz](mailto:s.benge@auckland.ac.nz)

**Direct dial:** +64 9 923 3585  
**Fax:** +64 9 373 7927

